🔥🐔 BizChicken 🐔🔥
Companies Similar to Blueprint Medicines Corporation
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
ABVC BioPharma, Inc.
ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1702, ABV-1601, ABV-1701 Vitargus
ABVC Bio Pharma, Inc., based in Fremont, California, is a clinical stage biopharmaceutical company developing drugs and medical devices to address unmet medical needs in the United States. The company is involved in developing therapies for conditions such as cancer, major depressive disorders, and attention deficit hyperactivity disorder.
Symbol: ABVC
Recent Price: $0.59
Industry: Biotechnology
CEO: Dr. Uttam Yashwant Patil Ph.D.
Sector: Healthcare
Employees: 16
Address: 44370 Old Warm Springs Boulevard, Fremont, CA 94538
Phone: 510 668 0881
Last updated: 2024-12-31
Gilead Sciences, Inc.
Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.
About | About | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | ESG | About | About | About | About | About | About | About | About | About | About | DEI | About | Locations | Contact | Contact | Contact | Careers | Careers | Careers | Careers | Careers | About | About | About | Careers | Jobs | Careers | About | Careers | DEI | Careers | Careers | Careers | Careers | Jobs | Careers | Careers | Careers | DEI | Careers | Careers | Careers | Careers | Careers | Jobs | About | About | About | About | About | About | Careers | Careers | Jobs | Jobs | Careers | Careers | Careers | About | About
Symbol: GILD
Recent Price: $92.01
Industry: Drug Manufacturers - General
CEO: Mr. Daniel P. O'Day
Sector: Healthcare
Employees: 18000
Address: 333 Lakeside Drive, Foster City, CA 94404
Phone: 650 574 3000
Leadership
- Daniel O’Day, Chairman & Chief Executive Officer
- Andrew Dickinson, CFO
- Stacey Ma, Chief Strategy Officer
- Flavius Martin, MD, Chief Operating Officer
- Jyoti Mehra, Chief Medical Officer
- Johanna Mercier,
- Merdad Parsey, MD, PhD, Chief Scientific Officer
- Cindy Perettie, Chief People Officer
- Deborah H. Telman,
- Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
- Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
- Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
- Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
- Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
- Harish Manwani, Senior Operating Partner, Blackstone Inc.
- Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
- Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
- John Smith, CEO
- Linda White, Chief Marketing Officer
- Robert Brown, Chief Operating Officer
- Michael Davis, President
- John Doe, CEO
- Jane Smith, CFO
- Emily Johnson, CTO
- Michael Brown, Director of Operations
- Linda Davis, Director
- Alice Johnson, CTO
- Susan Martinez, Chairman
- Jane Doe, CFO
- James Davis, Chairman
- Patricia Miller, President
Last updated: 2024-12-31
Regeneron Pharmaceuticals, Inc.
EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb
Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.
About | Leadership | About | History | About | About | Contact | Careers | Careers | Jobs | Jobs | Jobs | Careers | Culture | DEI | Careers | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Careers | Careers | Careers | Locations | Locations | Locations | Locations | Events | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Site Map | Careers | About | About | About | About | Jobs | About | Leadership | Careers | Careers | About | Jobs | Jobs | Careers
Symbol: REGN
Recent Price: $702.59
Industry: Biotechnology
CEO: Dr. Leonard S. Schleifer M.D., Ph.D.
Sector: Healthcare
Employees: 14165
Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
Phone: 914 847 7000
Leadership
- Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
- George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
- Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
- Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
- Leonard Brooks, Senior Vice President, Treasurer
- John Calabro, Senior Vice President, Internal Audit
- Christina Chan, Senior Vice President, Corporate Affairs
- Larry Coury, PhD, Senior Vice President, Associate General Counsel
- Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
- Matthew Everett, Senior Vice President, Global Procurement
- Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
- Rick Hall, Senior Vice President, Human Resources
- Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
- Nouhad Husseini, Senior Vice President, Business Development
- Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
- Melissa Lozner, Senior Vice President, Chief Compliance Officer
- Marion McCourt, Executive Vice President, Commercial
- Bob McCowan, Senior Vice President, IT and Chief Information Officer
- Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
- Richard O’Neal, Senior Vice President, Market Access
- Sally A. Paull, Executive Vice President, Human Resources
- Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
- George Poth, Senior Vice President, Real Estate & Facilities Management
- Alessandra Ravetti, Senior Vice President, Associate General Counsel
- Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
- David Snow, Senior Vice President, Global Head, Dupixent Franchise
- Mark Volpe, Senior Vice President, Tax
- Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
- Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
- Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
- Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
- Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
- Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
- Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
- Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
- Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
- Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
- Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
- Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
- Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
- Christos Kyratsous, PhD, Senior Vice President, Research
- Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
- John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
- Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
- Lynn Macdonald, PhD, Senior Vice President, Research
- Lori Morton, PhD, Senior Vice President, Research
- Andrew Murphy, PhD, Executive Vice President, Research
- Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
- William Olson, PhD, Senior Vice President, Therapeutic Proteins
- Mohammed Shameem, PhD, Senior Vice President, Formulations Development
- L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
- Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
- Neil Stahl, PhD, Executive Vice President, Research and Development
- Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
- Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
- Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
- Frederick Austin, Senior Vice President, Quality Control, Raheen
- Christine Childrose, Senior Vice President, Human Resources and HR Operations
- David Crenshaw, Senior Vice President, Associate General Counsel
- Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
- Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
- Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
- Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
- Scott Oberman, Senior Vice President, Supply Chain Operations
- David Simon, Senior Vice President, IOPS Finance and Business Operations
- Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
- Benjamin Yocum, Senior Vice President, Manufacturing Operations
- James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
- Bonnie L. Bassler, PhD, Director
- Michael S. Brown, MD, Director
- N. Anthony Coles, MD, Chair of the Board
- Joseph L. Goldstein, MD, Director
- Kathryn Guarini, PhD, Director
- Christine A. Poon, Lead Independent Director
- Arthur F. Ryan, Director
- Huda Y. Zoghbi, MD, Director
- Samantha Dickon, Director, Development Program Management
- Gervasio Batista, Sr. Scientist, Neuroscience
- James K. Gibson, Senior Regional Director, Immunology/Pulmonary
- Beth Brause, Director, Field Reimbursement Management
- Eric Prendergast, Director, Pricing Strategy
- Ashley Neff, Manager, Digital Communications
- Shari Loock, Associate Director, Sourcing
- Jennifer Davidson Hamilton, VP and Head of Precision Medicine
- Yi Zhang, Director, Health Economics & Outcomes Research
- Wilson Caldwell III, Director, GCO Vendor & Relationship Management
- David Stein, Director, Medical Operations
- Regeneron, Corporate
- Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
- Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
- Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
- Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
- Jessie Brown, Manager, Integrative Translational Genetics
- Gisu Eom, Lead Cloud DevOps Engineer
- Carmen Kenworthy, Scientist, Velocigene
- Ralph Hazlewood, Sr. Manager, Research Program Management
- Brandy Bennett, Sr. Director, R&D Strategy & Operations
Last updated: 2024-12-31
Voyager Therapeutics, Inc.
VY-AADC
Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies, with a lead clinical candidate VY-AADC for Parkinson's disease, as well as preclinical programs for various neurological disorders.
About | Vision/Values | Leadership | Vision/Values | Careers | Benefits | Careers | Careers | About | About | Careers | Culture | About
Symbol: VYGR
Recent Price: $5.59
Industry: Biotechnology
CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Sector: Healthcare
Employees: 162
Address: 75 Sidney Street, Cambridge, MA 02139
Phone: 857 259 5340
Leadership
- Alfred Sandrock, M.D., Ph.D.,
- Todd Carter, Ph.D., Chief Scientific Officer
- Jacquelyn Fahey Sandell, Chief Legal Officer
- Toby Ferguson, M.D., Ph.D., Chief Medical Officer
- Nathan Jorgensen, Ph.D., MBA, Chief Financial Officer
- Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO
- Michelle Quinn Smith, Chief Human Resources Officer
- Robin Swartz, Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer
- Michael Higgins, Chair
- Grace E. Colón, Ph.D.,
- James Geraghty,
- Steven Hyman, M.D,
- Catherine J. Mackey, Ph.D.,
- Jude Onyia, Ph.D.,
- Glenn Pierce, M.D., Ph.D.,
- George Scangos, Ph.D.,
- Nancy Vitale,
- Guangping Gao, Ph.D., Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.
- Dinah Sah, Ph.D., Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.
- Phillip Zamore, Ph.D., Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.
Last updated: 2024-12-31
Acrivon Therapeutics, Inc. Common Stock
Acrivon Predictive Precision Proteomics
Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.
Symbol: ACRV
Recent Price: $5.41
Industry: Biotechnology
CEO: Dr. Peter Blume-Jensen M.D., Ph.D.
Sector: Healthcare
Employees: 58
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 617-207-8979
Last updated: 2024-12-31
Akebia Therapeutics, Inc.
Vadadustat
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.
Symbol: AKBA
Recent Price: $1.85
Industry: Biotechnology
CEO: Mr. John P. Butler MBA
Sector: Healthcare
Employees: 167
Address: 245 First Street, Cambridge, MA 02142
Phone: 617 871 2098
Last updated: 2024-12-31
Apollomics, Inc.
APL-101 (Vebreltinib), APL-102, APL-122
Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.
Symbol: APLM
Recent Price: $10.13
Industry: Biotechnology
CEO: Dr. Guo-Liang Yu Ph.D.
Sector: Healthcare
Employees: 45
Address: 989 East Hillsdale Blvd, Foster City, CA 94404
Phone: 650 209 4055
Last updated: 2024-12-31
Arvinas, Inc.
Bavdegalutamide, ARV-471, ARV-766
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is based in New Haven, Connecticut and collaborates with organizations like Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.
About | Leadership | Contact | Culture | Culture | Culture | About | News | Events | ESG | About | About | About | About | About | About | About | About | About | About | About | About | Events | ESG | About | About | About | About | About | About | About | Culture | Culture | Vision/Values | Culture | Careers | About | About | About | About | News | About | About | Contact | About | About
Symbol: ARVN
Recent Price: $19.00
Industry: Biotechnology
CEO: Dr. John G. Houston Ph.D.
Sector: Healthcare
Employees: 445
Address: 5 Science Park, New Haven, CT 06511
Phone: 203 535 1456
Leadership
- John G. Houston, Ph.D., Chairperson, Chief Executive Officer, and President
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer
- Angela M. Cacace, Ph.D., Chief Scientific Officer
- Jared Freedberg, J.D., General Counsel and Corporate Secretary
- Paul McInulty, Senior Vice President, Regulatory Affairs
- John Northcott, Chief Commercial Officer
- Kelly Page, Senior Vice President, Global Head of Oncology Strategy and Program Leadership
- Andrew Saik, Chief Financial Officer
- Lisa Sinclair, Senior Vice President, Corporate Operations
- Ian Taylor, Ph.D., President, R&D
- Randy Teel, Ph.D., Chief Business Officer
- Steve Weiss, Senior Vice President, Chief Human Resources Officer
Last updated: 2024-12-31
Aerovate Therapeutics, Inc.
AV-101
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for rare cardiopulmonary diseases, with a lead product AV-101 for pulmonary arterial hypertension.
Symbol: AVTE
Recent Price: $2.66
Industry: Biotechnology
CEO: Mr. Timothy P. Noyes M.B.A.
Sector: Healthcare
Employees: 51
Address: 930 Winter Street, Waltham, MA 02116
Phone: 617 443 2400
Last updated: 2024-12-31
Avalo Therapeutics, Inc.
AVTX-002, AVTX-007, AVTX-801
Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.
Symbol: AVTX
Recent Price: $7.80
Industry: Biotechnology
CEO: Dr. Garry A. Neil M.D.
Sector: Healthcare
Employees: 19
Address: 540 Gaither Road, Rockville, MD 20850
Phone: 410 522 8707
Leadership
- Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
- Mittie Doyle, MD, FACR, Chief Medical Officer
- Chris Sullivan, Chief Financial Officer
- Paul Varki, Chief Legal Officer
- Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
- Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
- Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
- June Almenoff, MD, PhD, President and Chief Medical Officer
- Mitchell Chan, Chief Financial Officer
- Jonathan Goldman, MD, CEO
- Aaron Kantoff, Managing Partner
- Gilla Kaplan, PhD, Independent Director
- Samantha Truex, CEO
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
BeiGene, Ltd.
BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy
Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.
About | About | Vision/Values | About | About | Culture | DEI | Culture | Leadership | About | Contact | Careers | Careers | Careers | Careers | About | About | About | About | About | Jobs | About | About | About
Symbol: BGNE
Recent Price: $183.81
Industry: Biotechnology
CEO: Mr. John V. Oyler
Sector: Healthcare
Employees: 10000
Address: 55 Cambridge Parkway, Cambridge, MA 02142
Phone: 781-801-1800
Leadership
- John V. Oyler, Co-Founder, Chairman and CEO
- Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
- Olivier Brandicourt, M.D., Director
- Margaret Dugan, M.D., Director
- Donald W. Glazer, Director
- Michael Goller, Director
- Anthony Hooper, Director
- Ranjeev Krishana, Director
- Michael Nuoqing Yi, Director
- Alessandro Riva, M.D., Director
- Corsee Sanders, Ph.D., Director
- Shalini Sharp, Director
- Steven Young, Ph.D., Acting Head of Medicinal Chemistry
- Ron Levy, M.D., Scientific Advisory Board
- Neal Rosen, M.D., Ph.D., Scientific Advisory Board
- Charles Sawyers, M.D., Scientific Advisory Board
- David Schenkein, M.D., Scientific Advisory Board
- Melika Davis, SVP & Global Head, Clinical Operations
- Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
- Tony Guo, Ph.D., SVP, Global Statistics & Data Science
- Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
- Graham Hardiman, Global Head of HR
- Shreya Devendra Jani, SVP, Corporate Affairs
- Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
- Yang Ji, Chief Compliance Officer
- Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
- Chan Lee, General Counsel
- Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
- Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
- Kyoung Lim, VP of Supply Chain
- Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
- Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
- Richard O’Keeffe, Head of Global Quality
- Jurij Petrin, M.D., Head of New Market Development
- Yan Qi, Ph.D., SVP, Head of Public Affairs
- Hongyu Qian, SVP, Medical Affairs
- Jason Radford, SVP, Strategy & Corporate Development
- Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
- Adam Roach, VP and Head of Asia Pacific
- Aaron Rosenberg, Chief Financial Officer
- Michael Schoen, Strategic Advisor and Special Assistant to the CEO
- Matt Shaulis, General Manager of North America
- Lai Wang, Ph.D., Global Head of R&D
- Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
- Beth Wensley, SVP, Head of Portfolio and Program Management
- Kimberly Wolf, SVP, Global Commercial Strategy & Operations
- Xiaobin Wu, Ph.D., President, Chief Operating Officer
- Eva Yin, Chief Commercial Officer, Greater China
Last updated: 2024-12-31
bluebird bio, Inc.
betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel
bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.
About | Leadership | DEI | About | About | About | Contact | Careers | About | About | About | About
Symbol: BLUE
Recent Price: $7.86
Industry: Biotechnology
CEO: Mr. Andrew Obenshain
Sector: Healthcare
Employees: 375
Address: 60 Binney Street, Cambridge, MA 02142
Phone: 339 499 9300
Leadership
- Sarah Alspach, Senior Vice President, External Affairs
- Rich Colvin, MD, PhD, Chief Medical Officer
- Kasra Kasraian, Senior Vice President, Technical Development and Operations
- Tom Klima, Chief Commercial & Operating Officer
- Andrew Obenshain, Chief Executive Officer
- Scott Shoemaker, Senior Vice President, Quality
- James Sterling, Chief Financial Officer
- Joe Vittiglio, Chief Business and Legal Officer
- Andrea Walton, Chief People Officer
- Leslie Wilder, Vice President, Head of Regulatory Science
- Mark Vachon, Chairman; Formerly of GE
- John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
- Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
- Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
- Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
- Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
- Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
- Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare
Last updated: 2024-12-31
Blueprint Medicines Corporation
AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782
Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, including treatment for systemic mastocytosis, gastrointestinal stromal tumors, hepatocellular carcinoma, and non-small-cell lung carcinoma.
About | About | Vision/Values | About | About | About | About | Contact | Contact | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | About | About | About | About | About | About | About | Careers | Vision/Values | About | About
Symbol: BPMC
Recent Price: $86.82
Industry: Biotechnology
CEO: Ms. Kathryn Haviland M.B.A.
Sector: Healthcare
Employees: 638
Address: 45 Sidney Street, Cambridge, MA 02139
Phone: 617 374 7580
Last updated: 2024-12-31
Incyte Corporation
JAKAFI, PEMAZYRE, ICLUSIG
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.
About | Leadership | Contact | Contact | Locations | Contact | Contact | Culture | Jobs | Culture | DEI | News | Events | About | About | Careers | Jobs | Careers | Careers | DEI | Culture | Careers | Culture | DEI | Careers | Locations | Careers | About | About | About | About | About | Careers | About | About | Culture
Symbol: INCY
Recent Price: $68.42
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Sector: Healthcare
Employees: 2524
Address: 1801 Augustine Cut-Off, Wilmington, DE 19803
Phone: 302 498 6700
Leadership
- Hervé Hoppenot, Chairman and Chief Executive Officer
- Paula J. Swain, Executive Vice President, Human Resources
- Pablo J. Cagnoni, M.D., President, Head of Research and Development
- Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
- Sheila A. Denton, J.D., Executive Vice President and General Counsel
- Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
- Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
- Denise Brashear, Vice President, Head of Global Communications
- Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
- Lee Heeson, Executive Vice President, Head of Incyte International
- Michael Morrissey, Executive Vice President and Head of Global Technical Operations
- Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
- Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
- Julian C. Baker, Managing Partner
- Jean-Jacques Bienaime, Former Chief Executive Officer
- Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
- Paul J. Clancy, Former Executive Vice President and Senior Advisor
- Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
- Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
- Katherine High, M.D., Former President and Head of Research and Development
- Susanne Schaffert, Ph.D., Former President
Last updated: 2024-12-31
Kala Pharmaceuticals, Inc.
KPI-012, EYSUVIS, INVELTYS
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.
Contact | Careers | Jobs | Careers | Careers | Careers | Careers | Leadership | Careers | Contact | Careers | Careers | Careers | About
Symbol: KALA
Recent Price: $6.87
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Mark T. Iwicki
Sector: Healthcare
Employees: 43
Address: 1167 Massachusetts Avenue, Arlington, MA 02476
Phone: 781 996 5252
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
AbbVie Inc.
HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, CREON, Synthroid, Linzess/Constella, Lupron
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a range of therapies including HUMIRA for autoimmune diseases and MAVYRET for HCV infection.
About | ESG | News | Locations | Locations | Locations | Locations | Locations | Locations | Locations | Locations | Locations | Locations | Locations | Locations | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Jobs | Careers | Careers | Careers | Careers | Careers | Jobs | Site Map | About | About | About | About | About | About | Jobs | Careers
Symbol: ABBV
Recent Price: $176.20
Industry: Drug Manufacturers - General
CEO: Mr. Robert A. Michael
Sector: Healthcare
Employees: 50000
Address: 1 North Waukegan Road, North Chicago, IL 60064-6400
Phone: 847 932 7900
Last updated: 2024-12-31
Aptevo Therapeutics Inc.
APVO436
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapeutic candidates to treat various forms of cancer, with a primary focus on APVO436, a bispecific T-cell engaging antibody for leukemia and myelodysplastic syndrome.
About | Leadership | Directors | About | Contact | About | Contact | Contact | Contact | About | Leadership | Directors | About | About | About | About | About | About | About | About | About | About | About
Symbol: APVO
Recent Price: $4.78
Industry: Biotechnology
CEO: Mr. Marvin L. White
Sector: Healthcare
Employees: 40
Address: 2401 4th Avenue, Seattle, WA 98121
Phone: 206 838 0500
Leadership
- Marvin L. White, President and Chief Executive Officer
- Jeff Lamothe, EVP and Chief Operating Officer
- Daphne Taylor, SVP and Chief Financial Officer
- Dirk Huebner, M.D., Chief Medical Officer
- SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs
Last updated: 2024-12-31
PaxMedica, Inc. Common Stock
PAX-101
Pax Medica, Inc., is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for treating intractable neurologic disorders. Their lead product, PAX-101, is an intravenous formulation of suramin for indications such as autism spectrum disorder and chronic fatigue syndrome.
Symbol: PXMD
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Howard J. Weisman
Sector: Healthcare
Employees: 6
Address: 303 South Broadway, Tarrytown, NY 10591
Phone: 914-987-2876
Last updated: 2024-12-31